Impact of the human papillomavirus (HPV) vaccine supply shortage on Tanzania’s national HPV vaccine introduction

Gavi, the Vaccine Alliance, and global partners were informed by HPV vaccine manufacturers of vaccine supply constraints in 2018. Due to insufficient supply, Gavi-eligible countries, such as Tanzania, needed to determine which age cohorts to vaccinate against HPV based on available vaccine stock. This commentary discusses Tanzania's experience with HPV vaccine introduction and decisions made based on vaccine supply constraints.

Authors: Anyie J.Li, Furaha Kyesi, William Mwengee, Alex Mphuru, Mary Rose Giattas, Berrington Shayo, Raphael Nshunju, Dafrossa Lyimo, Anagha Loharikar